Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

NCT01330966 is registered in ClinicalTrials.gov with Emerald Clinical Inc. as lead sponsor.

NCT NCT01330966
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01330966 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
Lead sponsor
Emerald Clinical Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2011
Completion date
February 28, 2018
Enrollment
47 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

chondrosarcoma, metastatic chondrosarcoma